HCRTR1抗体;HCRTR1 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human renal cancer tissue using P11300(HCRTR1 Antibody) at dilution 1/100. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P11300(HCRTR1 Antibody) at dilution 1/100. (Original magnification: ×200)    

  
  

The hypocretin receptor 1 (HCRTR1), also known as orexin receptor type 1. is a G protein-coupled receptor primarily expressed in the brain, particularly in regions regulating arousal, reward, and stress responses. It binds to hypocretin neuropeptides (orexin-A and orexin-B), which are produced in the lateral hypothalamus and play critical roles in maintaining wakefulness, appetite, and energy homeostasis. HCRTR1 antibodies are tools developed to detect, quantify, or modulate this receptor in research and clinical contexts.

These antibodies are widely used in immunohistochemistry, Western blotting, and flow cytometry to study receptor localization, expression levels, and signaling pathways. Dysregulation of HCRTR1 is implicated in disorders such as narcolepsy (linked to hypocretin deficiency), insomnia, and addiction. Antibodies targeting HCRTR1 have also been explored for therapeutic applications, including blocking receptor activity in sleep disorders or modulating feeding behaviors.

Research using HCRTR1 antibodies has advanced understanding of its role in circadian rhythms and metabolic processes. For example, HCRTR1 antagonists like suvorexant, derived from antibody-guided structural studies, are approved for insomnia treatment. However, challenges remain in ensuring antibody specificity due to structural similarities with HCRTR2. Ongoing studies focus on refining antibody design to improve diagnostic accuracy and therapeutic potential in neuropsychiatric and metabolic diseases.